Marie-France Jilderda

Marie-France Jilderda

Auto-generated profile, based on publicly available information

Marie-France Jilderda

Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
MJMarie-France Jilderda
Marie-France Jilderda
YZYi Zhang
Yi Zhang
VRValerie Rebattu
Valerie Rebattu
RSRanelle Salunga
Ranelle Salunga
WMWilma Mesker
Wilma Mesker
GLGerrit-Jan Liefers
Gerrit-Jan Liefers
Purpose: This study assessed the prognostic ability of the breast cancer index (BCI) to identify patients at a minimal risk (<5%) of 10-year distant recurrence (DR) who are unlikely to benefit from adjuvant endocrine therapy. Experimental Design: This prospective translational study included postmenopausal patients with early-stage, hormone receptor–positive N0 breast cancer from the Stockholm (STO-3) trial who underwent surgery alone (“untreated”) or surgery plus adjuvant tamoxifen (“treated”) and from the Netherlands Cancer Registry (surgery alone). The primary endpoint was time to DR. An adjusted BCI model with an additional cutpoint was developed, which stratified patients into four prognostic risk groups. Results: Across cohorts, 16% to 22% of patients were classified as minimal risk of 10-year DR. In the Stockholm untreated cohort (n = 283), risks in the minimal-, low-, intermediate-, and high-risk groups were 2.3%, 15.5% [hazard ratio, 4.71 (95% confidence interval, 1.09–20.29) vs. minimal risk], 19.8% [6.97 (1.61–30.18)], and 35.9% [13.21 (3.07–56.76)], respectively (P < 0.001). In the Stockholm treated cohort (n = 317), risks were 4.3%, 5.0% [1.16 (0.35–3.85)], 11.7% [2.45 (0.74–8.14)], and 21.1% [5.27 (1.72–16.16); P < 0.001]. In the Netherlands Cancer Registry cohort (n = 1245), risks were 4.5%, 7.5% [subdistribution hazard ratio, 1.67 (95% confidence interval, 0.81–3.45)], 10.3% [2.40 (1.14–5.03)], and 13.1% [3.13 (1.50–6.55); P = 0.005]. BCI risk scores provided additional independent information over standard prognostic factors (likelihood ratio, χ2 = 7.98; P = 0.004). Conclusions: The adjusted BCI model identified women with early-stage, hormone receptor–positive N0 breast cancer at a minimal risk of DR who may consider de-escalating adjuvant endocrine therapy.

3 June 2025
Verified
Other
Open access
MJMarie-France Jilderda
Marie-France Jilderda
YZYi Zhang
Yi Zhang
VRValerie Rebattu
Valerie Rebattu
RSRanelle Salunga
Ranelle Salunga
WMWilma Mesker
Wilma Mesker
GLGerrit-Jan Liefers
Gerrit-Jan Liefers
Purpose:This study assessed the prognostic ability of the breast cancer index (BCI) to identify patients at a minimal risk (<5%) of 10-year distant recurrence (DR) who are unlikely to benefit from adjuvant endocrine therapy.Experimental Design:This prospective translational study included postmenopausal patients with early-stage, hormone receptor–positive N0 breast cancer from the Stockholm (STO-3) trial who underwent surgery alone (“untreated”) or surgery plus adjuvant tamoxifen (“treated”) and from the Netherlands Cancer Registry (surgery alone). The primary endpoint was time to DR. An adjusted BCI model with an additional cutpoint was developed, which stratified patients into four prognostic risk groups.Results:Across cohorts, 16% to 22% of patients were classified as minimal risk of 10-year DR. In the Stockholm untreated cohort (n = 283), risks in the minimal-, low-, intermediate-, and high-risk groups were 2.3%, 15.5% [hazard ratio, 4.71 (95% confidence interval, 1.09–20.29) vs. minimal risk], 19.8% [6.97 (1.61–30.18)], and 35.9% [13.21 (3.07–56.76)], respectively (P < 0.001). In the Stockholm treated cohort (n = 317), risks were 4.3%, 5.0% [1.16 (0.35–3.85)], 11.7% [2.45 (0.74–8.14)], and 21.1% [5.27 (1.72–16.16); P < 0.001]. In the Netherlands Cancer Registry cohort (n = 1245), risks were 4.5%, 7.5% [subdistribution hazard ratio, 1.67 (95% confidence interval, 0.81–3.45)], 10.3% [2.40 (1.14–5.03)], and 13.1% [3.13 (1.50–6.55); P = 0.005]. BCI risk scores provided additional independent information over standard prognostic factors (likelihood ratio, χ2 = 7.98; P = 0.004).Conclusions:The adjusted BCI model identified women with early-stage, hormone receptor–positive N0 breast cancer at a minimal risk of DR who may consider de-escalating adjuvant endocrine therapy.

3 June 2025
Verified
Other
Open access
MJMarie-France Jilderda
Marie-France Jilderda
YZYi Zhang
Yi Zhang
VRValerie Rebattu
Valerie Rebattu
RSRanelle Salunga
Ranelle Salunga
WMWilma Mesker
Wilma Mesker
GLGerrit-Jan Liefers
Gerrit-Jan Liefers
Prognostic performance of the four BCI risk groups in Stockholm and NCR cohorts.

3 June 2025
Verified
Other
Open access
MJMarie-France Jilderda
Marie-France Jilderda
YZYi Zhang
Yi Zhang
VRValerie Rebattu
Valerie Rebattu
RSRanelle Salunga
Ranelle Salunga
WMWilma Mesker
Wilma Mesker
GLGerrit-Jan Liefers
Gerrit-Jan Liefers
Performance of the adjusted BCI model in the Stockholm cohorts. The new cutpoint for the BCI minimal-risk group was trained using the untreated patients. (A) Untreated and (B) TAM-treated. TAM, tamoxifen.

3 June 2025
Verified
Other
Open access
MJMarie-France Jilderda
Marie-France Jilderda
YZYi Zhang
Yi Zhang
VRValerie Rebattu
Valerie Rebattu
RSRanelle Salunga
Ranelle Salunga
WMWilma Mesker
Wilma Mesker
GLGerrit-Jan Liefers
Gerrit-Jan Liefers
CONSORT diagram for patient selection in the NCR cohort.

3 June 2025
Verified
Other
Open access
MJMarie-France Jilderda
Marie-France Jilderda
YZYi Zhang
Yi Zhang
VRValerie Rebattu
Valerie Rebattu
RSRanelle Salunga
Ranelle Salunga
WMWilma Mesker
Wilma Mesker
GLGerrit-Jan Liefers
Gerrit-Jan Liefers
Patient clinicopathologic characteristics in the Stockholm and NCR cohorts.